Medicare Part D premiums have looked relatively stable for the past three years, holding in a range most beneficiaries could plan around without much drama. That stability wasn't really a market outcome, it was a temporary government subsidy quietly propping up the number underneath it, and starting in 2027, that subsidy goes away entirely. The national bid amount insurers use to build their Part D plans is set to jump by roughly a quarter for the coming year, a shift regulators themselves acknowledge is tied directly to the subsidy's expiration rather than any sudden change in underlying drug costs.
The subsidy in question, a premium stabilization program tied to the broader overhaul of Part D under the Inflation Reduction Act, was explicitly designed as a temporary bridge, not a permanent feature. According to Medicare's own payment advisory commission, it was reducing the average standalone Part D premium by roughly sixteen dollars a month in 2026, meaning the roughly thirty-six dollar average premium most enrollees have been paying would have been closer to fifty-two dollars without it. Beneficiaries weren't experiencing the real cost of the redesigned Part D benefit for the past few years. They were experiencing a subsidized version of it, and the bill for the difference is arriving now.
Why This Ends Right as Other Costs Rise Too
The timing compounds the effect in a way that isn't a coincidence so much as several separate policy clocks running out at once. The standard Part D deductible is rising from 615 dollars to 700 dollars for 2027. The annual out-of-pocket cap, the ceiling beyond which Medicare covers the full cost of covered drugs, is rising from 2,100 dollars to 2,400 dollars the same year. None of these changes are hidden or improperly disclosed, they're published, scheduled adjustments. But a beneficiary who's only been tracking their own monthly premium, the number that's felt stable for three straight years, is about to see multiple cost components move upward in the same enrollment cycle, right as the subsidy that had been softening one of those numbers disappears entirely.
The Mechanics of a Number That Was Never the Real Number
Here's the structural lesson worth taking from this, useful well beyond just this specific subsidy: a government stabilization program can make a premium look flat or predictable for years while the underlying cost trend it's masking keeps moving in the background. Medicare regulators have said plainly that insurers have now had enough experience under the redesigned Part D benefit to build their bids without the subsidy's support, which is effectively an acknowledgment that insurers' actual cost assumptions were higher than the subsidized premium reflected the whole time. The subsidy didn't change what drug coverage actually cost to provide. It changed what portion of that real cost showed up on the beneficiary's own bill versus what got absorbed elsewhere, and now that absorption stops.
Why "It's Been Stable" Isn't the Same as "It's Sustainable"
This distinction matters because it changes how a beneficiary should read years of apparent premium stability going forward. A premium staying flat for three years under an explicitly temporary program is a very different signal than a premium staying flat because underlying costs genuinely held steady, even though both look identical from the beneficiary's side while the subsidy is active. Anyone who assumed the past few years of modest, predictable Part D premiums reflected a durable new normal was, without necessarily realizing it, relying on a countdown clock that regulators had scheduled to expire in 2027 from the start.
What to Actually Do Heading Into This Year's Enrollment
None of this means every beneficiary will see a dramatic premium increase, plan-specific amounts will vary considerably, and some plans may absorb more of the change than others. But three years of stable-looking Part D premiums were never proof that drug coverage costs had stopped rising, they were proof that a temporary subsidy was successfully hiding the increase from view, and that subsidy's scheduled expiration means this year's plan comparison during open enrollment matters more than the past several years combined. The practical step is treating this fall's open enrollment period as a genuine re-shopping exercise rather than a formality, since the plan that looked like the stable, reasonable choice for the past three years may no longer be priced the same way once the subsidy underneath it is gone.
— John Stone